# US 2019/0376971 A1 · Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376971 A1
- Document ID: US20190376971A1
- Status: Published application
- Kind: A1
- Application number: 16/477,395
- Filed: 2018-01-19
- Published: 2019-12-12
- Earliest claimed: 2017-01-19
- Assignees: Acerta Pharma B.V.
- Applicants: Acerta Pharma B.V.
- Inventors: Tjeerd Barf; Allard Kaptein; Saskia Verkaik; Dennis Demont; Todd Covey; Bas Van De Kar; Bart Van Lith; Michael Gulrajani
- Web page: https://patentgrep.com/patent/US20190376971A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- C07D 495/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C12Q 1/485: {involving kinase}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

In some embodiments, the invention relates to compositions, methods, and kits for assessment of drug target occupancy in Bruton's tyrosine kinase (BTK) in a selective and sensitive manner for use with BTK inhibitor therapy in the treatment of Bruton's tyrosine kinase (BTK) mediated disorders, including cancers, inflammatory diseases, and immune and autoimmune diseases.

## Claims

### Claim 1

A method for determining a drug target occupancy of Bruton's tyrosine kinase (BTK) in a patient after treatment of the patient with a BTK inhibitor, comprising the steps of:
(a) obtaining a tissue sample from the patient;
(b) separating a population of cells from the tissue sample;
(c) contacting a BTK probe with the population of cells;
(d) detecting the amount of BTK bound to the BTK probe using an assay;
(e) determining the drug target occupancy of BTK in the population of cells based on the amount of BTK bound to the BTK probe; and
(f) optionally performing a second assay for PLCγ2 phosphorylation;
wherein the BTK probe is a compound according to:
or a salt or complex thereof, wherein:
X is CH or S;
Y is C(R6);
Z is CH or bond;
A is CH;
B1 is N or C(R7);
B2 is N or C(R8);
B3 is N or CH;
B4 is N or CH;
R1 is C(═O)R11,
R2 is (C1-3)alkyl;
R3 is (C1-3)alkyl;
R2 and R3 form a (C3-7)heterocycloalkyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and morpholinyl, optionally substituted with one or more fluorine, hydroxyl, (C1-3)alkyl, or (C1-3)alkoxy;
R4 is H;
R5 is H, halogen, cyano, (C1-4)alkyl, (C1-3)alkoxy, (C3-6)cycloalkyl, or any alkyl group of which is optionally substituted with one or more halogen;
R6 is H or (C1-3)alkyl;
R7 is H, halogen or (C1-3)alkoxy;
R8 is H or (C1-3)alkyl; or
R7 and R8 form, together with the carbon atom they are attached to a (C6-10)aryl or (C1-9)heteroaryl;
R5 and R6 together may form a (C3-7)cycloalkenyl or (C2-6)heterocycloalkenyl, each optionally substituted with (C1-3)alkyl or one or more halogen;
with the proviso that 0 to 2 atoms of B1, B2, B3, and B4 are N;
R11 is selected from the group consisting of (C2-6)alkenyl-R12 and (C2-6)alkynyl-R12; and
R12 is L1-L2-(L3)m-(L4-)n-W, wherein:
L1 is selected from the group consisting of heterocycloalkyl and heteroalkyl;
L2 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
L3 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
L4 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
m is 0 to 5;
n is 0 to 5; and
W is:

### Claim 2 (depends on 1)

The method of claim 1, wherein L1 is selected from the group consisting of:
—O—, —(C1-5)alkoxy-, and —[(C1-10)alkyl]amino-.

### Claim 3 (depends on 1)

The method claim 1, wherein R12 is:

### Claim 4 (depends on 1)

The method of claim 1, wherein the assay is an enzyme-linked immunosorbent assay (ELISA).

### Claim 5 (depends on 1)

The method of claim 1, wherein the tissue sample is selected from the group consisting of blood, lymphatic tissue, and tumor biopsy tissue.

### Claim 6 (depends on 5)

The method of claim 5, wherein the tissue sample is blood, and wherein the population of cells are peripheral blood mononuclear cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the BTK probe is a compound selected from the group consisting of:
and salts or complexes thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the BTK inhibitor is selected from the group consisting of ibrutinib, acalabrutinib, ONO-4059, and pharmaceutically-acceptable salts, esters, prodrugs, cocrystals, solvates, or hydrates thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the BTK inhibitor is acalabrutinib.

### Claim 10 (depends on 1)

The method of claim 1, further comprising the step of adjusting a therapeutic regimen based on the drug target occupancy of BTK.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient is suffering from a BTK-mediated disorder.

### Claim 12 (depends on 11)

The method of claim 11, wherein the BTK mediated disorder is selected from the group consisting of chronic lymphocytic leukemia, small lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, Hodgkin's lymphoma, B cell acute lymphoblastic leukemia, Burkitt's lymphoma, Waldenström's macroglobulinemia, multiple myeloma, myelofibrosis, bladder cancer, head and neck cancer, pancreatic cancer, colon cancer, breast cancer, fibrosarcoma, mesothelioma, renal cell carcinoma, lung carcinoma, thyoma, prostate cancer, colorectal cancer, ovarian cancer, acute myeloid leukemia, thymus cancer, brain cancer, squamous cell cancer, skin cancer, eye cancer, retinoblastoma, melanoma, intraocular melanoma, oral cavity cancer, oropharyngeal cancer, gastric cancer, stomach cancer, cervical cancer, head and neck cancer, renal cancer, kidney cancer, liver cancer, prostate cancer, esophageal cancer, testicular cancer, gynecological cancer, thyroid cancer, glioblastoma, esophogeal tumors, hematological neoplasms, acquired immune deficiency syndrome (AIDS)-related lymphoma, Kaposi's sarcoma, viral-induced cancer, non-small-cell lung cancer, small-cell lung cancer, chronic myelocytic leukemia, hepatitis C virus infection, hepatocellular carcinoma, metastatic colon cancer, primary central nervous system lymphoma, ovary tumor, tumor angiogenesis, chronic inflammatory disease, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, psoriasis, eczema, scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma and melanoma, ulcerative colitis, atopic dermatitis, pouchitis, spondylarthritis, uveitis, Behcets disease, polymyalgia rheumatica, giant-cell arteritis, sarcoidosis, Kawasaki disease, juvenile idiopathic arthritis, hidratenitis suppurativa, Sjögren's syndrome, psoriatic arthritis, juvenile rheumatoid arthritis, ankylosing spoldylitis, Crohn's Disease, lupus, and lupus nephritis.

### Claim 13

A compound according to:
or a salt or complex thereof, wherein:
X is CH or S;
Y is C(R6);
Z is CH or bond;
A is CH;
B1 is N or C(R7);
B2 is N or C(R8);
B3 is N or CH;
B4 is N or CH;
R1 is C(═O)R11,
R2 is (C1-3)alkyl;
R3 is (C1-3)alkyl;
R2 and R3 form a (C3-7)heterocycloalkyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and morpholinyl, optionally substituted with one or more fluorine, hydroxyl, (C1-3)alkyl, or (C1-3)alkoxy;
R4 is H;
R5 is H, halogen, cyano, (C1-4)alkyl, (C1-3)alkoxy, (C3-6)cycloalkyl, or any alkyl group of which is optionally substituted with one or more halogen;
R6 is H or (C1-3)alkyl;
R7 is H, halogen or (C1-3)alkoxy;
R8 is H or (C1-3)alkyl; or
R7 and R8 form, together with the carbon atom they are attached to a (C6-10)aryl or (C1-9)heteroaryl;
R5 and R6 together may form a (C3-7)cycloalkenyl or (C2-6)heterocycloalkenyl, each optionally substituted with (C1-3)alkyl or one or more halogen;
with the proviso that 0 to 2 atoms of B1, B2, B3, and B4 are N;
R11 is selected from the group consisting of (C2-6)alkenyl-R12 and (C2-6)alkynyl-R12; and
R12 is L1-L2-(L3)m-(L4-)n-W, wherein:
L1 is selected from the group consisting of heterocycloalkyl and heteroalkyl;
L2 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
L3 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
L4 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
m is 0 to 5;
n is 0 to 5; and
W is:

### Claim 14 (depends on 13)

The compound of claim 13, wherein L1 is selected from the group consisting of:
—O—, —(C1-5)alkoxy-, and —[(C1-10)alkyl]amino-.

### Claim 15 (depends on 13)

The compound of claim 13, wherein R12 is:

### Claim 16 (depends on 13)

The compound of claim 13, wherein the compound is selected from the group consisting of:
and salts or complexes thereof.

### Claim 17

(canceled)

### Claim 18

A kit for determining drug target occupancy in a patient receiving BTK inhibitor therapy, comprising a BTK probe according to:
or a salt or complex thereof, wherein:
X is CH or S;
Y is C(R8);
Z is CH or bond;
A is CH;
B1 is N or C(R7);
B2 is N or C(R8);
B3 is N or CH;
B4 is N or CH;
R1 is C(═O)R11,
R2 is (C1-3)alkyl;
R3 is (C1-3)alkyl;
R2 and R3 form a (C3-7)heterocycloalkyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and morpholinyl, optionally substituted with one or more fluorine, hydroxyl, (C1-3)alkyl, or (C1-3)alkoxy;
R4 is H;
R5 is H, halogen, cyano, (C1-4)alkyl, (C1-3)alkoxy, (C3-6)cycloalkyl, or any alkyl group of which is optionally substituted with one or more halogen;
R6 is H or (C1-3)alkyl;
R7 is H, halogen or (C1-3)alkoxy;
R8 is H or (C1-3)alkyl; or
R7 and R8 form, together with the carbon atom they are attached to a (C6-10)aryl or (C1-9)heteroaryl;
R5 and R6 together may form a (C3-7)cycloalkenyl or (C2-6)heterocycloalkenyl, each optionally substituted with (C1-3)alkyl or one or more halogen;
with the proviso that 0 to 2 atoms of B1, B2, B3, and B4 are N;
R11 is selected from the group consisting of (C2-6)alkenyl-R12 and (C2-6)alkynyl-R12; and
R12 is L1-L2-(L3)m-(L4-)n-W, wherein:
L1 is selected from the group consisting of heterocycloalkyl and heteroalkyl;
L2 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
L3 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
L4 is a linear linker group selected from the group consisting of (C1-5)alkylamide, (C1-5)alkoxy, and a bond;
m is 0 to 5;
n is 0 to 5; and
W is:

### Claim 19 (depends on 18)

The kit of claim 18, wherein L1 is selected from the group consisting of:
—O—, —(C1-5)alkoxy-, and —[(C1-10)alkyl]amino-.

### Claim 20 (depends on 18, 19)

The kit of any of claim 18 or 19, wherein R12 is:

### Claim 21 (depends on 18)

The kit of claim 18, wherein the BTK probe is a compound selected from the group consisting of:
and salts or complexes thereof.

### Claim 22

(canceled)

### Claim 23

(canceled)
